1xbet APK Takeda Pharmaceutical Co., Ltd.
1xbet APK., Ltd.

- Takeda has applied 1xbet APK approval of TAKECAB_®OD 10 mg and TAKECAB_®OD 20 mg asadditional 1xbet APKmulations of TAKECAB_® 10 mg and TAKECAB_®20 mg, developed by Takeda 1xbet APK treating acid-related disease

Takeda Pharmaceutical Co., Ltd. (Takeda) and 1xbet APK., Ltd. (Otsuka) announced today that Takeda has applied for approval to manufacture and market TAKECAB_®OD 10 mg and TAKECAB_®OD 20 mg as additional 1xbet APKmulations of TAKECAB_®10 mg and TAKECAB_®20 mg, developed by Takeda 1xbet APK treating acid-related disease.

The application 1xbet APK approval is based on a human bioequivalence study conducted in Japan (TAK-438ODT-1001) and dissolution tests.

TAKECAB OD tablets are suitable for patients with impaired swallowing, including elderly patients, and the increase in treatment options can also be expected to improve medication adherence. Based on a domestic co-promotion agreement concluded in 2014, Takeda will manufacture and sell TAKECAB OD tablets, with informational activities conducted jointly by 1xbet APK and Takeda.